Claudication: Exercise vs Endoluminal Revascularization (CLEVER) study update  by Murphy, Timothy P. et al.
CLINICAL TRIALS UPDATE
Thomas L. Forbes, MD, Section Editor
Claudication: Exercise vs Endoluminal
Revascularization (CLEVER) study update
Timothy P. Murphy, MD,a Alan T. Hirsch, MD,b,c Donald E. Cutlip, MD,d Judith G. Regensteiner, PhD,e
Anthony J. Comerota, MD,f Emile Mohler, MD,g David J. Cohen, MD, MSc,h and Joseph Massaro, PhD;i
on behalf of the CLEVER Investigators*, Providence, RI; Minneapolis, Minn; Boston, Mass; Denver, Colo; Toledo,
Ohio; Philadelphia, Pa; and Kansas City, Mo
The Claudication: Exercise vs Endoluminal Revascularization (CLEVER) Study is a prospective multicenter randomized
clinical trial designed to compare the relative clinical and cost-effectiveness of invasive revascularization with stents to
supervised exercise rehabilitation in a cohort with moderate to severe claudication due to aortoiliac insufficiency. The
study is currently enrolling at twenty-eight sites in the US and Canada. Enrollment of 217 participants is planned, with
data collected at baseline, six months, and 18months. The primary study endpoint is maximumwalking duration (MWD)
on a graded treadmill test; secondary endpoints include community-based walking, markers of cardiovascular disease risk
(body mass index, waist circumference, blood pressure, lipid profile, glucose tolerance, and plasma fibrinogen),
health-related quality of life, and cost effectiveness. There are currently sixty randomized participants; recruitment is
projected to end in July 2010 and final study results reported in June 2012. (J Vasc Surg 2009;50:942-5.)The Claudication: Exercise vs Endoluminal Revascular-
ization Study (CLEVER) is a National Institutes of Health-
sponsored partially blinded prospective, multicenter random-
ized clinical trial that tests the hypothesis that stent placement
results in improved exercise treadmill test performance com-
pared with supervised exercise rehabilitation for people with
claudication due to aortoiliac insufficiency.1Data are collected
at baseline, six months, and 18 months. There are multiple
secondary endpoints, including measurement of community-
*See Appendix 1 for CLEVER Investigators.
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942based walking using pedometers, physiological variables asso-
ciated with coronary heart disease risk (bodymass index, waist
circumference, blood pressure, lipid profile, glucose tolerance,
C-reactive protein, and fibrinogen), health-related quality of
life, and cost effectiveness.1 The rationale for the study is that
although stent-based revascularization may achieve arterial
patency and improve symptoms, it is a local treatment for a
systemic disease that may or may not improve community-
based walking and patient satisfaction and whose relative
efficacy and durability compared with exercise training is not
established. Increasing activity levels is proven to be important
to lower rates of myocardial infarction and stroke. Supervised
exercise rehabilitation, supported by provision of exercise-
focused behavioral medicine component in CLEVER, is de-
signed to improve claudication symptoms andwalking ability.
Improved walking ability and activity levels may result in
weight loss, improved blood pressure and lipid profiles, im-
proved glycemic control, and fewer heart attacks, strokes, and
cardiovascular-related deaths.
THE CLEVER STUDY TREATMENT PROGRAM
Study participants commit to an 18-month timeframe
of participation, with data collected at baseline, six months,
and 18 months. There are currently three treatment groups
with asymmetric randomization including optimal medical
care for 20% of patients (instructions to perform home
exercise), supervised exercise rehabilitation (three times a
week for six months with 12 months follow-up with a
behavioral intervention) for 40% and aortoiliac stent place-
ment for 40%. A combined stent plus supervised exercise
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discontinued. All study participants receive cilostazol as a
background claudication therapy throughout the course of
their participation in the study, as long as the medication is
well-tolerated, since cilostazol has been proven to improve
walking ability in those with claudication.2 Exercise ses-
sions for individuals in this group are provided three times
a week for one hour per session. Upon completing super-
vised exercise, the participant is contacted by a health
educator, who begins a program of regular contact de-
signed to foster adoption of regular exercise between six
and 18 months. A combined stent plus supervised exercise
treatment group, originally included as an exploratory anal-
yses of this potential additive or synergistic benefit, has
been discontinued so that recruitment could be focused on
the primary study endpoints.
For all study participants, anatomic eligibility is deter-
mined by arterial imaging studies and/or by use of noninva-
sive tests without regard to “anatomic suitability” for revascu-
larization by stent or TransAtlantic InterSociety Consensus
(TASC) classification of the lesion. A secondary recruitment
and treatment plan that would expand study inclusion to
participants with only femoropopliteal artery stenoses1 was
considered as a potentially important expansion of the
CLEVER study goals to a particularly relevant contemporary
symptomatic PAD cohort. However, inclusion of this ex-
panded study population was not activated due to concerns
that aorto-iliac and femoropopliteal revascularization might
be associatedwith differential relative treatment effects. Amer-
ican College of Sports Medicine and American Heart Associ-
ation/American College of Cardiology (AHA/ACC) exclu-
sions for individuals who could not reliably undergo exercise
training and exercise testing, respectively, are also utilized
(Table I, online only).
ENROLLMENT AND STUDY TIMELINE:
LESSONS FOR THE VASCULAR HEALTHCARE
COMMUNITY
There are currently twenty-eight active enrollment cen-
ters in CLEVER (Table II, online only), and current plans are
to activate as many as 30 US sites and four Canadian sites. As
of April 2009, there are 60 participants enrolled. Slow recruit-
ment has been often observed in “strategy of care” random-
ized trials.3 Nevertheless, since the study does not use a
time-to-event endpoint, slow recruitment does not affect
study power and the sponsor, the National Heart, Lung, and
Blood Institute, is very committed to getting the important
data the CLEVER will produce. Enrollment is scheduled to
end in July of 2010, and given 18months of follow-up, study
results should be available by June 2012.
We note that a major component of the recently signed
American Recovery and Reinvestment Act is money for in-
creasing comparative effectiveness research, with one of the
studies specifically mentioned being a comparison of invasive
versus noninvasive treatment for people with “. . . leg pain
that results from blockage of the arteries in the lower legs.”4
The treatment of PAD is extremely costly,5 and the durability
and effectiveness of current treatments needs to be demon-strated to ensure reimbursement in the future. Clearly the
community of vascular healthcare professionals needs to par-
ticipate more actively in multicenter randomized clinical trials
like CLEVER, as do practitioners focused on other diseases
such as cancer, heart disease, and infectious diseases, in order
to acquire the knowledge of how best to manage the patients
that they serve and to ensure reimbursement for their services.
National Institutes ofHealthmulticenter clinical trials of PAD
will prove to be the most important PAD studies of our time
and will validate care and payor policy well into the future.
POPULATION
Ascertainment of eligibility is satisfactory to date, with
only one participant enrolled who was found to not have
aortoiliac insufficiency but rather had femoropopliteal ar-
tery obstruction only. However, eligibility criteria were not
followed correctly for this participant, but according to
intention-to-treat principles they remain in their assigned
treatment group. The population currently has an average
age of 65.2 9.5 years, has a 2:1 male predominance, and is
approximately 20% ethnic minorities, with 37.5% reporting
prior myocardial infarction, 23.4% with prior coronary artery
revascularization, and 25% a history of diabetes mellitus.
PARTICIPANT FOLLOW-UP AND DATA
COLLECTION
Compliance with the CLEVER study protocol has been
satisfactory and well within assumptions made for power cal-
culations. Four study participants have elected to withdraw
from subsequent follow-up, and data compliance for partici-
pants remaining in the study is over 90%. Of the other 20
participants in the supervised exercise group, compliance with
supervised exercise has been excellent, with subjects achieving
an average of 72% attendance of a total of 78 (26 weeks, three
times a week) exercise sessions scheduled for each participant.
Since the study sample size was inflated by 30%, this high
compliance with the study protocol and high rate of complete
data collection demonstrates that CLEVER is likely to have
sufficient power to definitively inform the primary study hy-
potheses on trial completion.
SAFETY
The CLEVER study compares treatment strategies that
are based on known treatments that have low risk. CLEVER
does not use any devices or drugs that are not approved by the
U.S. Food andDrug Administration. The safety profile of the
study has been excellent, with no unanticipated device or
exercise-related adverse events, and only three significant ad-
verse events observed, none felt to be related to a study
treatment.
OUTCOMES
CLEVER has been designed to provide one planned
interim data evaluation, which will occur after half of the
study participants have completed their six-month follow-
up visit. Subject compliance data do not suggest any clini-
cally relevant outcome advantage or disadvantage for any
treatment group. Acceptance of supervised exercise has
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ments in exercise performance for all treatment groups.
Whether this anecdotal experience will translate into a
better relative treatment effect for any treatment group will
await formal analysis.
CONCLUSIONS
CLEVER represents one of the most important random-
ized clinical trials that is designed to evaluate the clinical
efficacy and risk of the three major claudication treatments,
and is underway with 48 patients randomized as of February
2009. The only existing randomized clinical trials have dem-
onstrated no benefit of treatment strategies that use only plain
balloon angioplasty or arterial stents as compared with super-
vised exercise.6,7 Payors including the federal government are
demanding data to support reimbursement for medical ser-
vices. Although all other aspects of study execution are satis-
factory, subject recruitment inCLEVERhas underperformed.
Although this is common in treatment strategy trials,3 it is
particularly relevant for the vascular community that has long
striven to have access to well-funded clinical trials. The
CLEVER study provides a unique opportunity to provide
important scientific evidence that will inform physicians and
patients regarding optimal management of people with clau-
dication, and we call on the vascular healthcare community to
take an enlightened stance on this and other PAD treatment
strategy trials, to embrace their role as scientists as well as
clinicians, and to contribute in spirit and in fact to the success-
ful completion of the CLEVER Study.
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Atherosclerotic peripheral arterial occlusive disease represents
a significant burden; both to patients who carry the diagnosis and
to the healthcare system. Claudication is simply one manifestation
of a systemic process, and recognition of this fact has fueled
comparative studies such as the Claudication: Exercise Versus
Endoluminal Revascularization (CLEVER) trial, described by
Murphy and colleagues, and updated in this issue of the Journal.1
Any contemporary comparative effectiveness trial examining clau-
dication should therefore focus not only on traditional measures of
claudication, but on the systemic effects of atherosclerosis, and the
economic sustainability of any proposed treatment strategy.
The rationale for the study is that anatomic-based treatment
alone does not offer the same potential benefits afforded to sys-
temic therapy, namely exercise therapy and medical optimization.
High-profile trials have demonstrated the equivalence of systemic
treatment to revascularization in the coronary vascular bed inmany
patient populations.2 The non-interventional cohorts in the
CLEVER study have the additive benefits of exercise therapy
(supervised and non-supervised) and represent appropriately
managed patients by contemporary standards. There are several
obvious critiques to the trial setup, including anatomic restric-
tion to the aortoiliac segment, lack of medical management
followed by conditional interventional therapy (patients who
fail conservative measures), and small sample size with restricted
follow-up, which will limit the ability to observe the potential
long-term benefits of sustained exercise therapy. Still, the col-
laborators are to be commended for executing a controlled
claudication trial designed to address the systemic management
of atherosclerosis.
The importance of randomized trials such as the CLEVER
study in vascular disease management cannot be overstated. Endo-
vascular treatments have undoubtedly lowered the morbidity of
revascularization procedures, and benefited enumerable patients.
However, the widespread adoption of endovascular therapy for the
stable disease process of claudication has largely been advanced
without rigorous trials and in many cases without proper attention
to the medical management of the systemic disease process. How-
ever, with a renewed interest in cost effective healthcare, there is an
avenue to reverse this trend.Comparative effectiveness research has been embraced by the
federal government, and in fact, funding has been set aside in the
America Recovery and Reinvestment Act. In this setting, multi-
center comparative trials such as this are essential to the process of
data-driven healthcare reform. Equipped with randomized trial
data, vascular providers will be able guide individual patient treat-
ment, freed from anecdotal reports and marketing-driven presen-
tations that support an array of untested procedures.
Furthermore, payors should have a keen interest in the cost-
efficacy outcomes from this trial. Should supervised exercise ther-
apy and medical optimization prove to be effective, there is a
potential to change the landscape so that these services, which are
not currently covered, become reimbursed. What more could
vascular providers, patients, and society want other than to reim-
burse a therapy that treats the systemic risk factors for atheroscle-
rosis and improves overall patient health?
Many critics of comparative effectiveness based care worry that
its application will threaten the personal nature of the doctor-
patient relationship.3 There is this potential, but vascular surgeons,
who are the only comprehensive providers of vascular care, should
welcome the opportunity to have real scientific data upon which to
recommend care to their patients, whether it be by medical,
interventional, or surgical means. The challenge to our specialty
will be to assume a prominent leadership role in trial design,
conduct, and real-world implementation, so as to provide individ-
ualized, financially responsible, and scientifically-driven care.
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Inclusion Criteria
1. Subject has symptoms suggestive of intermittent claudication,
discomfort, involving large muscle groups of the leg(s) (calf, th
2. Subject is 40 years old.
3. Claudication score consistent with “Rose,” “atypical,” or “non
pendix A for acceptable responses).
4. Positive noninvasive evaluation for significant aortoiliac PAD o
a. Contrast arteriography: Contrast arteriogram showing at lea
tery, OR
b. Computed tomographic angiography (CTA) or magnetic re
mon iliac artery, external iliac artery, accompanied by a biph
(loss of early diastolic flow reversal or loss of forward flow d
c. Duplex ultrasound: Occlusion or focal doubling of peak sys
accompanied by a biphasic or monophasic Doppler wave fo
or loss of forward flow during diastole), OR
d. Vascular noninvasive physiologic tests: Ankle-brachial index
ankle if arteries are incompressible*) with resting thigh-brac
tolic acceleration time 140 msec [these tests may be orde
*Abnormal PVR waveform must lack augmentation at t
downslope, and must be reviewed by the core lab.
Note:MRA/CTA, and contrast arteriogram images ima
waveform tracings to the Noninvasive Test Committee
5. Highest ankle pressure reduced by at least 25 mm Hg after exe
Doppler signal for both the posterior tibial and anterior tibial a
Note: The highest ankle pressure result is determined by using
measurement.
6. Subject has moderate to severe claudication symptoms, defined
line (initial) Gardner treadmill test (see Appendix B).
7. Performance on a second Gardner treadmill test within 25% of
Exclusion Criteria
1. Presence of critical limb ischemia (Rutherford Grade II or III
acute limb ischemia (pain, pallor, pulselessness, paresthesias, p
2. Common femoral artery (CFA) occlusion or 50% stenosis b
tolic velocity in the ipsilateral common femoral artery by dup
by angiography, MRA, or CTA, (inadequate outflow for iliac
3. Known total aortoiliac occlusion from the renal arteries to the
4. Participant has bilateral claudication symptoms and the limb t
ciency as described in inclusion criterion number 4.
5. Participant has bilateral claudication symptoms, but both limb
aortoiliac insufficiency as described in inclusion criterion num
6. Subject meets the following exclusions based upon modified
i. Ambulation limited by co-morbid condition other than c
1. Severe coronary artery disease
2. Angina pectoris
3. Chronic lung disease
4. Neurological disorder such as hemiparesis
5. Arthritis, or other musculoskeletal conditions includin
ii. Poorly-controlled hypertension (SBP  180 mm Hg).
iii. Poorly-controlled diabetes mellitus.
iv. Other active significant medical problems such as cancer, kn
or renal replacement therapy), known chronic liver disease o
7. Contraindication to exercise testing according to AHA/ACC
unstable angina, uncontrolled cardiac arrhythmias causing sym
atic severe aortic stenosis, acute pulmonary embolus or pulmo
performance or be aggravated by exercise such as infection, th
ity that would preclude safe and adequate test performance, k
stenosis or its equivalent, moderate stenotic valvular heart dis
arrhythmias or bradyarrhythmias, hypertrophic cardiomyopat
gree atrioventricular block.
8. Arterial insufficiency of target lesion due to restenosis of an an
9. Recent (3 months) infrainguinal revascularization (surgery
10. Recent major surgery in the last 3 months.
11. Abdominal aortic aneurysm 4 cm or iliac artery aneurysm 
12. Patients who are pregnant, planning to become pregnant, or
13. Unwilling or unable to attend regular (three times a week) su
with each prospective participant}such as exercise-induced pain, cramps, fatigue, or other equivalent
igh, buttocks), relieved by rest.
calf” claudication by San Diego Claudication Questionnaire (see Ap-
n the most symptomatic side(s) (bilaterally if symptoms are equal):
st 50% stenosis in the aorta, common iliac artery, or external iliac ar-
sonance angiography (MRA): At least 60% stenosis in the aorta, com-
asic or monophasic Doppler wave form at the common femoral artery
uring diastole), OR
tolic velocity in the aorta, common iliac artery, or external iliac artery,
rm at the common femoral artery (loss of early diastolic flow reversal
0.9 (or abnormal ankle pulse volume recording (PVR) waveform at
hial index (thigh-BI) 1.1, and common femoral artery Doppler sys-
red for study screening].
he ankle, have a delayed, rounded systolic peak, and straight or convex
gesmust be submitted to the Clinical Coordinating Center andDoppler
for over read pre- or post-randomization.
rcise compared to resting pressure (or loss of previously present
rteries immediately after exercise if arteries were incompressible).
the higher result of either the dorsalis pedis or posterior tibial artery
as less than 11 minutes maximum walking duration (MWD) at base-
the initial baseline MWD test result.
12 PAD, defined as pain at rest, ischemic ulceration, gangrene) or
aralysis) in either leg.
y angiography, MRA, CTA, or duplex ultrasound or doubling of sys-
lex ultrasound, or 50% diameter stenosis by visual estimate in the CFA
stent intervention), if available pre-randomization.
common iliac arteries (all other occlusions ARE eligible).
hat is more symptomatic does not show evidence of aortoiliac insuffi-
s are equally symptomatic and one side does not show evidence of
ber 4.
American College of Sports Medicine criteria for exercise training:
laudication, for example:
g amputation
own chronic renal disease (serum creatinine2.0 mg/dL within 60 days
r anemia, active substance abuse, or known history of dementia.
guideline, specifically: Acute myocardial infarction (within 3-5 days),
ptoms or hemodynamic compromise, active endocarditis, symptom-
nary infarction, acute noncardiac disorder that may affect exercise
yrotoxicosis, acute myocarditis or pericarditis, known physical disabil-
nown thrombosis of the lower extremity, known left main coronary
ease, electrolyte abnormalities, known pulmonary hypertension, tachy-
hy, mental impairment leading to inability to cooperate, or high de-
gioplasty/stent or bypass is not eligible.
or endovascular intervention).
1.5 cm is present.
lactating.
pervised exercise sessions. {Please review this commitment carefully14. Weight 350 lbs or 159 kg (may exceed treadmill and angiography table limits).
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15. Language barrier exists for primary Quality of Life instruments (available in English and Spanish).
16. Inability to understand and sign informed consent forms due to cognitive or language barriers (interpreter permitted).
17. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, car-
diorespiratory collapse, or equivalent) and which would preclude patient from participation in angiographic procedures.
18. Allergy to stainless steel or nitinol.
19. Nonatherosclerotic cause of PAD (fibromuscular dysplasia, dissection, trauma, etc).
20. Inability to walk on a treadmill without grade at a speed of at least 2 mph for at least two minutes on the first treadmill test.
21. ST-segment depression 1 mm in any of the standard 12 electrocardiogram leads or sustained (30 seconds) arrhythmia other
than tachycardia or occasional premature atrial or ventricular contractions during exercise testing.
22. Post-exercise systolic blood pressure within the first five minutes after eligibility treadmill test lower than pre-exercise systolic blood
pressure.
23. A peak heart rate 80% of maximum (calculated by subtracting age from 220) while reporting “onset” of claudication symptoms
during the second baseline examination.
24. Repeat treadmill test shows an MWD result that is 25% different than the subject’s initial Gardner treadmill test result.
25. Current active involvement in a supervised exercise program (eg, with a trainer, exercise protocol, and goals, such as in cardiac orpulmonary rehabilitation) for more than two weeks within the prior six weeks.Table II (online only). Enrolling centers and site principal investigators (as of February 10, 2009)
Site Principal investigator
Rhode Island Hospital, Providence, RI Timothy Murphy, MD
Abbott Northwestern Hospital/Minneapolis Heart Institute Foundation, Minneapolis, Minn Alan Hirsch, MD
Henry Ford Hospital, Detroit, Mich Jonathan Ehrman, PhD
Jobst Vascular Center, Toledo, Ohio Anthony Comerota, MD
Vascular and Endovascular Specialists of Ohio, Mansfield, Ohio William Miller, MD
Torrance Memorial Medical Center, Torrance, Calif Mark Lurie, MD
Ochsner Clinic, New Orleans, La Willie Chi, MD
VA Ann Arbor, Ann Arbor, Mich Venkat Krishnamurthy, MD
Forsyth Medical Center, Winston-Salem, NC Daniel Golwyn, MD
Providence Medical Research Center, Spokane, Wash Stuart Cavalieri, MD
St. Joseph Hospital, Orange, Calif Mahmood Razavi, MD
Stony Brook Hospital, Stony Brook, NY Apostolos Tassiopoulos, MD
University of Pennsylvania, Philadelphia, Pa Emile Mohler, MD
VA Central Arkansas, Little Rock, Ark Mahmoud Moursi, MD
VA Palo Alto, Palo Alto, Calif Fritz Bech, MD
Oregon Health Sciences University, Portland, Ore John Kaufman, MD
Iowa Clinic, Des Moines, Iowa John Matsuura, MD
Mayo Clinic, Rochester, Minn Audra Duncan, MD
Johns Hopkins Hospital, Baltimore, Md Elizabeth Ratchford, MD
Methodist Hospital, Houston, Tex Mark Davies, MD
University of California-Davis, Sacramento, Calif David Dawson, MD
Asheville Cardiology, Asheville, NC William Abernathy, MD
Rapides Regional Medical Center, Alexandria, La William Long, MD
Baptist Cardiac and Vascular Institute, Kendall, Fla Barry Katzen, MD
Capital Health Center, Halifax, Nova Scotia, Canada Robert Berry, MD
Northwestern Memorial Hospital, Chicago, Ill Jon Matsumura, MD
Charleston Area Medical Center, Charleston, WVa Aravinda Nanjundappa, MD
